In preclinical experiments, abemaciclib is a potent, selective cell growth inhibitor, inhibiting preferentially the CDK4/Cyclin D1 complex and leading to cell senescence and cell death in breast cancer cell lines with broad molecular profiles. The gene discussed is CCND1; the disease is breast carcinoma.